Development of improved soluble inhibitors of FasL and CD40L based on oligomerized receptors
- 17 March 2000
- journal article
- Published by Elsevier in Journal of Immunological Methods
- Vol. 237 (1-2) , 159-173
- https://doi.org/10.1016/s0022-1759(99)00239-2
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- Monocyte-mediated Tumoricidal Activity via the Tumor Necrosis Factor–related Cytokine, TRAILThe Journal of Experimental Medicine, 1999
- Characterization of Structural Domains of Human Osteoclastogenesis Inhibitory FactorPublished by Elsevier ,1998
- Heteronuclear NMR assignments and secondary structure of the coiled coil trimerization domain from cartilage matrix protein in oxidized and reduced formsProtein Science, 1997
- CD40 Ligand Is Required for Protective Cell-Mediated Immunity to Leishmania majorImmunity, 1996
- Functions of CD40 and Its Ligand, gp39 (CD40L)Critical Reviews in Immunology, 1996
- Induction of apoptosis in mature T cells by tumour necrosis factorNature, 1995
- Fas(CD95)/FasL interactions required for programmed cell death after T-cell activationNature, 1995
- Autocrine T-cell suicide mediated by APO-1/(Fas/CD95)Nature, 1995
- Molecular cloning and expression of the fas ligand, a novel member of the tumor necrosis factor familyCell, 1993
- The Pathophysiology of Tumor Necrosis FactorsAnnual Review of Immunology, 1992